Axsome Therapeutics, Inc. (AXSM) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Axsome Therapeutics, Inc. (AXSM) closed at USD 162.22 on 2026-10-14, a change of +21.5 % over the past year, with a market capitalization of USD 8.47B.

Axsome Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Axsome Therapeutics, Inc. key figures

Previous close

USD 162.22 (2026-10-14)

1-year change

+21.5 %

Market cap

USD 8.47B

Enterprise value

USD 8.38B

P/E ratio (trailing)

-41.81

P/E ratio (forward)

40.06

EPS (trailing)

-3.87

EPS (forward)

4.04

PEG ratio

n/a

Price to book

101.56

Revenue growth

45.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.80

Employees

1,346

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Axsome Therapeutics, Inc. and compare it with other stocks.